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Background and Purpose: FK506 and rapamycin are modulators of FK-binding
proteins (FKBP) that are used to suppress immune function after organ and
hematopoietic stem cell transplantations. The drugs share the unwanted side-effect
of evoking hypertension that is associated with reduced endothelial function and
nitric oxide production. The underlying mechanisms are not understood. FKBP may
regulate IP3 receptors (IP3R) and ryanodine receptors (RyR) to alter Ca
2+ signalling in
endothelial cells.
Experimental Approach: We investigated the effects of FK506 and rapamycin on
Ca2+ release via IP3R and RyR in hundreds of endothelial cells, using the indicator
Cal-520, in intact mesenteric arteries from male Sprague-Dawley rats. IP3Rs were
activated by acetylcholine or localised photo-uncaging of IP3, and RyR by caffeine.
Key Results: While FKBPs were present, FKBP modulation with rapamycin did not
alter IP3-evoked Ca
2+ release. Conversely, FK506, which modulates FKBP and blocks
calcineurin, increased IP3-evoked Ca
2+ release. Inhibition of calcineurin (okadiac acid
or cypermethrin) also increased IP3-evoked Ca
2+ release and blocked FK506 effects.
When calcineurin was inhibited, FK506 reduced IP3-evoked Ca
2+ release. These
findings suggest that IP3-evoked Ca
2+ release is not modulated by FKBP, but by
FK506-mediated calcineurin inhibition. The RyR modulators caffeine and ryanodine
failed to alter Ca2+ signalling suggesting that RyR is not functional in native
endothelium.
Conclusion and Implications: The hypertensive effects of the immunosuppressant
drugs FK506 and rapamycin, while mediated by endothelial cells, do not appear to be
exerted at the documented cellular targets of Ca2+ release and altered FKBP binding
to IP3 and RyR.
1 | INTRODUCTION
FK506 (also known as tacrolimus) and rapamycin (sirolimus) are
immunosuppressant drugs that are used widely in organ transplantation
to prevent tissue rejection (Jeanmart et al., 2002; Lemos et al., 2003;
Abbreviations: 2-APB, 2-aminoethoxydiphenyl borate; F, fluorescence intensity; F0, baseline
fluorescence intensity; FKBPs, FK-binding proteins; IP3, inositol 1,4,5-trisphosphate; IP3R,
inositol 1,4,5-trisphosphate receptors; RyR, ryanodine receptors.
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Wallemacq et al., 2009; Wallemacq & Reding, 1993). Rapamycin is
also used in drug-eluting stents to prevent re-stenosis in patients with
coronary artery disease (Abizaid, 2007; Serruys, Regar, & Carter,
2002). While the drugs are effective immunosuppressants, FK506
and rapamycin have the undesirable effect of causing hypertension in
up to 70% of patients that are treated with the drugs (Lindenfeld
et al., 2004; Lindenfeld et al., 2005; Taylor et al., 1999). The underly-
ing causes of this immunosuppressant-induced hypertension are not
understood, but disruption of normal endothelial function and
decreased production of the endogenous vasodilator NO are reported
contributors (De Lima et al., 1999; Takeda, Miyamori, Furukawa,
Inaba, & Mabuchi, 1999).
Endothelial function and NO production are critically controlled
by the cytoplasmic Ca2+ concentration. In turn, endothelium-derived
Ca2+-dependent mediators control vascular tone, nutrient exchange,
blood cell recruitment, blood clotting, and the formation of new blood
vessels (see Feletou, 2011). The endoplasmic reticulum (ER), the
intracellular Ca2+ store, is of particular importance in regulating the
cytoplasmic Ca2+ concentration in endothelial cells (Tran & Watanabe,
2006) from which release is controlled by two major channel receptor
complexes—the inositol 1,4,5-trisphosphate receptors (IP3R) and
ryanodine receptors (RyR). While the contribution of IP3R is of
acknowledged significance in regulating Ca2+, the role of RyR in
endothelial cells in intact arteries is less certain.
The cytoplasmic receptors for the immunosuppressant drugs
FK506 and rapamycin have been identified as the FK-binding
proteins (FKBPs; Bierer et al., 1990; Harding, Galat, Uehling, &
Schreiber, 1989). FKBPs are accessory proteins of IP3R and RyR on
the internal Ca2+ store. The association of FKBP with the IP3R and
RyR is disrupted by FK506 and rapamycin and may change channel
activity with consequences for Ca2+ signalling (Bultynck, De Smet,
et al., 2001; Cameron, Steiner, Sabatini, et al., 1995; Dargan, Lea, &
Dawson, 2002). Indeed, changes in the association of FKBPs with
the channels may evoke significant effects on cardiovascular
function. Genetic deletion of FKBP12.6 in mice causes hypertension
(Long, Cook, Wu, & Mitchell, 2007). In rats, FK506 decreased
production of the endothelium-derived vasodilator NO and
increased the production of the contractile agent endothelin
(Takeda et al., 1999). In human and rat resistance arteries in vitro,
FK506 increased the sensitivity to noradrenaline and impaired
vasodilation to ACh and sodium nitroprusside (De Lima et al.,
1999). Reduced endothelium-dependent relaxation was also
reported in mouse aorta after FK506 treatment (Chiasson et al.,
2011; Cook, Chiasson, Long, Wu, & Mitchell, 2009). These findings
raise the possibility that IP3R and RyR may contribute to the altered
endothelial function induced by the immunosuppressant drugs.
However, the precise nature of the control that FKBP might exert
on IP3R and RyR is uncertain.
In the case of IP3R, some investigations have found removal of
FKBP12 decreased IP3-mediated Ca
2+ release (MacMillan, Currie,
Bradley, Muir, & McCarron, 2005), while (in bilayer studies) addition
of exogenous FKBP12 increased IP3R channel activity (Dargan et al.,
2002). These results suggest that FKBP12 potentiates IP3R activity.
On the other hand, FKBP12 may inhibit channel activity, and removal
of FKBP12 from the channel increased IP3R-mediated Ca
2+ release in
rat cerebral microsomes and smooth muscle (Cameron, Steiner,
Sabatini, et al., 1995). Despite the importance of IP3-mediated Ca
2+
release to the control of endothelial function, there are no
investigations that have examined FKBP regulation of IP3-mediated
Ca2+ release in endothelial cells.
FKBP12 may also associate with RyR (Bradley, Currie, MacMillan,
Muir, & McCarron, 2003; Bultynck, De Smet, et al., 2001; Carmody,
Mackrill, Sorrentino, & O'Neill, 2001; MacMillan et al., 2005;
MacMillan, Currie, & McCarron, 2008; Tang, Chen, Zou, Campbell, &
Li, 2002; Wang et al., 2004; Zheng et al., 2004). Removal of FKBPs
from RyR by either FK506 or rapamycin increased RyR channel open
probability in lipid bilayers (Kaftan, Marks, & Ehrlich, 1996; Tang et al.,
2002) and Ca2+ signals in intestinal, colonic, bladder, and pulmonary
artery myocytes (Bielefeldt, Sharma, Whiteis, Yedidag, & Abboud,
1997; MacMillan et al., 2008; Weidelt & Isenberg, 2000; Zheng et al.,
2004). In mesenteric and human small resistance arteries, FK506
induced vasoconstriction (De Lima et al., 1999; Schwertfeger,
Wehrens, Oberhauser, Katzenwadel, & Rump, 2001), while in rat vas
deferens, rapamycin decreased phenylephrine-induced contractions
as a result of Ca2+ leak via RyR (Scaramello, Muzi-Filho, Zapata-Sudo,
Sudo, & Cunha Vdo, 2009). FKBP12.6 deficient mice showed
increased spontaneous Ca2+ release from the internal store when
compared with wild type urinary bladder myocytes (Ji et al., 2004).
Rebinding either FKBP12 or FKBP12.6, following their removal,
decreased channel opening (Barg, Copello, & Fleischer, 1997;
Brillantes et al., 1994; Bultynck, Rossi, et al., 2001; Mayrleitner,
What is already known
• FK506 and rapamycin modulate FK-binding proteins
(FKBP) but share the side effect of evoking hypertension.
• Hypertension induced by FK506 and rapamycin is associ-
ated with reduced endothelial function and NO
production.
What this study adds
• FK506 increases IP3-evoked Ca
2+ release by calcineurin
inhibition; rapamycin does not increase IP3-evoked Ca
2+
release.
• RyR activation failed to evoke Ca2+ release, and
ryanodine does not alter endothelial Ca2+ signals.
What is the clinical significance
• The hypertensive effects of FK506 and rapamycin are
not FKBP-mediated in endothelial cells.
• IP3-mediated Ca
2+ release may be modulated indirectly
by FK506 through inhibition of calcineurin.
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Timerman, Wiederrecht, & Fleischer, 1994; Timerman et al., 1993).
There are also reports of Ca2+ release via RyR being altered by FKBP
in endothelial cells. In cultured mouse aortic endothelial cells
depletion of FKBP increased endothelial intracellular Ca2+ leak via
RyR, suggesting that FKBP stabilized the channel in the closed state
(Cook et al., 2009; Long et al., 2007). Furthermore, rapamycin or
FK506 decreased NO production and endothelium-dependent
dilation and increased systolic BP (Long et al., 2007).
However, evidence does not universally support a role of
FKBPs in regulating either RyR or IP3R activity. In some studies, no
interaction was found to occur between FKBP and either RyR
(Carmody et al., 2001; Murayama et al., 1999; Wang et al., 2004;
Zheng et al., 2004) or IP3R (Bultynck, De Smet, et al., 2001;
Carmody et al., 2001; Thrower et al., 2000; Zheng et al., 2004).
Functional studies also failed to detect any effect of the drug
FK506 or protein FKBP on IP3-mediated Ca
2+ release (Boehning &
Joseph, 2000; Bultynck, De Smet, et al., 2001; Bultynck et al., 2000;
Kanoh et al., 1999) or RyR channel function (Barg et al., 1997;
duBell, Wright, Lederer, & Rogers, 1997; Epstein, Beall, Wynn,
Mulloy, & Brophy, 1998; Timerman et al., 1996; Xiao et al., 2007;
Yasutsune et al., 1999).
In addition to binding to the IP3R and RyR, FKBPs may regulate
kinase and phosphatase activity. The different modes of action
of separate signalling pathways may account, in part, for the
contradictory findings on IP3R and RyR modulation by FKBP. Removal
of FKBP from either IP3R or RyR by FK506 results in the formation of
a FK506-FKBP complex, which inhibits the Ca2+/calmodulin-depen-
dent serine/threonine phosphatase calcineurin (Liu et al., 1991). Cal-
cineurin may mediate the immunosuppressive actions of FK506 (Liu
et al., 1992), contribute to various cellular functions (Guerini, 1997;
Klee, Ren, & Wang, 1998), and regulate RyR and IP3R to control Ca
2+
release (Bandyopadhyay, Shin, Ahn, & Kim, 2000; Cameron et al.,
1997; Cameron, Steiner, Roskams, et al., 1995; Cameron, Steiner,
Sabatini, et al., 1995; MacMillan et al., 2008; Shin et al., 2002). In sup-
port, calcineurin inhibitors increased caffeine- and ryanodine-induced
Ca2+ release and the frequency and amplitude of Ca2+ oscillations in
cardiac and skeletal muscle (Bandyopadhyay, Shin, Ahn, & Kim, 2000;
Shin et al., 2002). In COS-7 cells and cerebellar microsomes, calcineurin
inhibition increased ATP-induced Ca2+ release and IP3R activity
(Bandyopadhyay, Shin, & Kim, 2000; Cameron, Steiner, Roskams, et al.,
1995) whereas expression of a constitutively active form of calcineurin
inhibited Ca2+ release (Bandyopadhyay, Shin, & Kim, 2000). Con-
versely, other studies have shown that drugs that inhibit calcineurin,
such as cypermethrin, cyclosporin A, or okadaic acid, did not alter
Ca2+ release via either RyR or IP3R (Ashizawa, Kobayashi, Tanaka, &
Nakayama, 1989; Avdonin et al., 1999; Cook et al., 2009; Frapier
et al., 2001; Hirano, Kanaide, & Nakamura, 1989; Macmillan &
McCarron, 2009; Zheng et al., 2004). The comparatively few studies
in endothelial cells also yielded contradictory findings. In cultured
endothelial cells (ECV304, BPAECs, and HPAECs), the calcineurin
inhibitors okadaic acid, cyclosporin A, or calyculin A evoked Ca2+
release from the ER (Hepworth, Lawrie, & Simpson, 1997; Kolozsvari
et al., 2012). However, calcineurin activity failed to alter Ca2+ in
cultured aortic endothelial cells (Cook et al., 2009). Together, these
studies highlight a confused picture of the regulation of endothelial
Ca2+ signalling by FKBP and its disruption via the immunosuppres-
sant drugs FK506 and rapamycin.
The present study was undertaken in view of the controversy
which surrounds the effects of the drugs FK506 and rapamycin on
intracellular Ca2+ release, their importance as immunosuppressant
drugs, associated hypertension side effects, and the absence of
information on the role of FKBP on IP3-mediated Ca
2+ release. Ca2+
was measured in endothelial cells of intact mesenteric arteries. Around
100 cells were analysed separately from each preparation and cellular
responses before and after various pharmacological interventions
were paired. The use of photolysed caged IP3 to activate IP3R mini-
mized the number of second messenger systems activated. The study
has shown that pharmacological modulation of FKBP from IP3R with
FK506 increased IP3-evoked Ca
2+ release. Cypermethrin and okadaic
acid (drugs which can inhibit calcineurin) each increased IP3-evoked
Ca2+ release and prevented the FK506-induced increase in Ca2+
release. Rapamycin, which removes FKBP from the receptors but does
not inhibit calcineurin, did not alter IP3-evoked Ca
2+ release. Thus, cal-
cineurin is required for the potentiation of IP3-evoked Ca
2+ release by
FK506. The RyR activator caffeine did not evoke Ca2+ release in the
endothelium in intact arteries, suggesting that RyR does not play a role
in endothelial Ca2+ modulation. Our results suggest that IP3R-medi-
ated Ca2+ release may be modulated (a) indirectly by FKBP through
inhibition of calcineurin, and (b) FKBPs by themselves do not appear
to regulate Ca2+ release in endothelial cells.
2 | METHODS
2.1 | Animals
All animal husbandry and experimental procedures were carried out
in accordance with the prior approval of the University of Strathclyde
Animal Welfare and Ethical Review Body and under relevant UK
Home Office Regulations (Schedule 1 of the Animals [Scientific
Procedures] Act 1986, UK). Strathclyde BPU is a conventional unit
which undertakes FELASA quarterly heath monitoring. Male
Sprague–Dawley rats (10–12 week old; 250–300 g), from an
in-house colony, were used for the study. The animals were housed
three per cage, and the cage type was North Kent Plastic model
RC2F with nesting material “Sizzle Nest.” A 12:12 light dark cycle
was used with a temperature range of 19–23C (set point 21C) and
humidity levels between 45% and 65%. Animals had free access to
fresh water and SDS diet RM1 (rodent maintenance). The enrichment
in the cages was aspen wood chew sticks and hanging huts. Animal
studies are reported in compliance with the ARRIVE guidelines
(Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the
recommendations made by the British Journal of Pharmacology
(McGrath & Lilley, 2015).
All experiments used either the aorta or second-order mesenteric
arteries (as described) obtained from male Sprague–Dawley rats
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(10–12 weeks old; 250–350 g), killed by an overdose of pentobarbital
sodium (200 mgkg−1, i.p.). Sprague–Dawley rats are a widely used
experimental model with a wealth of background information to
aid interpretation of results. Controls and experimental treatments
were carried out in the same tissue, so blinding and randomization
were not used.
2.2 | Mesenteric artery preparation and mounting
Arteries were prepared as previously described (Wilson, Lee, &
McCarron, 2016). In brief, the mesenteric bed was removed
immediately following killing. Second-order mesenteric arteries were
dissected and opened longitudinally using microscissors. The arteries
were pinned out on a Sylgard block using 50-μm diameter wire
with the endothelial layer exposed. Throughout this procedure,
preparations were kept in physiological salt solution (PSS; 145-mM
NaCl, 2-mM MOPS, 4.7-mM KCl, 1.2-mM NaH2PO4, 5-mM glucose,
0.02-mM EDTA, 1.17-mM MgCl2, 2-mM CaCl2, pH 7.4). Arteries
were then incubated with the Ca2+ indicator Cal-520 (5 μM) with
0.02% Pluronic F-127 for 30 min at 37C. After washing in PSS,
preparations were placed face down on 200-μm diameter stainless
steel pins on a 0 grade thickness coverslip that was fixed to the
bottom of a custom bath chamber (3 cm × 1.5 cm; Wilson, Lee, &
McCarron, 2016).
2.3 | Mesenteric artery image acquisition and
analysis
Images were acquired using a Nikon Eclipse TE300 inverted
microscope body with a 40× 1.3 NA Nikon S Fluor oil-immersion
objective lens, imaged onto an Andor iXon EMCCD camera,
cropped to 512 × 512 pixels. A CoolLED pE-300 LED system with
405/488/561 nm excitation light was used in conjunction with
custom-designed FITC/TRITC excitation and emission filters and
beamsplitter. All acquisition was performed through MicroManager
v1.4.22 (Edelstein et al., 2014).
2.4 | Localized IP3 uncaging
A Rapp Optoelectronics flash lamp (00-325-JML-C2) used at 200 V
produced light of ~1-ms duration, which was passed through a
395-nm short pass filter into a 1250-μm diameter light guide
(McCarron et al., 2010; Olson, Chalmers, & McCarron, 2012). The light
guide was fixed to a spot illumination adaptor, mounted onto
the epi-illuminator of the microscope and focussed using broadband
light. For each imaging session, an image was taken using this
broadband light to identify the uncaging region. The uncaging region
had a diameter of ~70 μm.
For uncaging, second-order mesenteric arteries were prepared as
previously described and incubated with 5-μM Cal-520 and 5-μM
membrane-permeant Ins(1,4,5)P3-caged IP3 (SiChem) in PSS for
30 min at 37C. Image acquisition was performed at 10 fps for 1,000
frames (1 min 40s), with uncaging performed after 15 s. Fifteen
minutes were left between each uncaging event to ensure Ca2+ stores
had fully replenished. All uncaging events were recorded in triplicate.
The endothelium was incubated with rapamycin (10 μM), FK506
(10 μM), okadaic acid (5 μM), or cypermethrin (10 μM) for 30 min
before repeat recordings on the same preparation were taken.
Preparations were incubated in 2-APB (500 μM) for 10 min.
2.5 | ACh-stimulated Ca2+ signalling
Arteries were mounted in custom-made imaging chambers. The
imaging chambers were fitted with a perfusion pump (set to
1.5 mlmin−1) to flow solutions and an aspirator to remove waste. To
avoid “run-up” of the ACh responses (Figure S1), preparations were
stimulated with ACh (50 nM) in PSS (15 min), washed with PSS
(15 min) twice before the experiments were started.
Experiments were performed in triplicate, with baseline
recordings followed by pharmacological perturbation. Images were
acquired at 10 fps for 2,000 frames (3 min 20 s) and washed for
20 min with PSS, all performed under flow (1.5 mlmin−1). Following
controls, arteries were incubated with FK506 (10 μM), okadaic acid
(5 μM), or cypermethrin (10 μM) for 30 min under no flow conditions
before repeat recordings were taken in the same preparation.
Preparations were incubated in 2-APB (500 μM) for 10 min.
2.6 | Effects of ryanodine on Ca2+ signalling
Arteries were prepared as previously described and incubated with
Cal-520 (5 μM) in PSS for 30 min at 37C. Image acquisition was per-
formed at 10 fps for 1,000 frames (1 min 40s), with stimulation per-
formed after 30 s. Fifteen minutes were left between each recording
session. Preparations were incubated with ryanodine (30 μM), caffeine
(10 mM), or combinations of both and stimulated with ACh (50 nM) as
described in the text.
2.7 | Image analysis
Image analysis was performed using methods adapted from Wilson,
Lee, and McCarron (2016). In brief, cell location and shift in cell
position between technical replicates were initially determined using
Fiji (RRID:SCR_002285) to create matched coordinates for each cell
over repeated imaging sessions. A semi-automated Python-based
code adapted from Wilson, Lee, and McCarron (2016), Wilson,
Saunter, Girkin, and McCarron (2016), and Wilson, Saunter, Girkin,
and McCarron (2015) was used to extract and process Ca2+ signals
from regions of interest placed on each cell. Raw signals were
expressed as baseline-corrected fluorescence intensity (F/F0) by
dividing each intensity trace by an averaged 100-frame baseline
period at the start of each trace. These signals were then smoothed
by a 21-point third-order polynomial Savitzky–Golay filter. Key curve
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parameters (e.g., amplitude, frequency, and number of cells) were
calculated using an automated algorithm and peaks identified using a
zero crossing detector for the derivative of the trace (Wilson, Lee, &
McCarron, 2016). The time and amplitude of these peaks could then
be extracted.
In uncaging experiments, before image analysis was performed, a
mask was applied to the raw data to only analyse cells in which IP3
was directly uncaged. The uncaging region occupied a fraction of the
overall field so these experiments had a lower number of cells per
experiment than ACh-evoked signalling.
To determine whether or not FK506 or rapamycin evoked “Ca2+
leak” from the internal store, the number of cells showing
spontaneous Ca2+ activity at baseline (Frames 1–150) were manually
counted for each biological replicate.
2.8 | Endothelial patch isolation
The aorta was dissected, collected into PSS with sodium pyruvate
(NaPy, 2 mM), the surrounding fat removed, washed, and pinned
out, removing any remaining blood. The aorta was then cut into
small strips and incubated in collagenase (Type 3, 2 mgml−1 in
PSS + 2 mM NaPy) for 20 min at 37C in a water bath. The colla-
genase was gently removed and PSS + 2 mM NaPy +1% BSA used
to gently wash the tissue three times. A glass Pasteur pipette was
cut to a length of ~2 cm, flame-sterilized and rounded off, and used
to titurate the tissue vigorously 20 times. Patches were then placed
on an EtOH-sterilized glass coverslip in an imaging chamber and left
to settle for 3 hr.
2.9 | Endothelial patch image acquisition
Patches were loaded with Cal-520 (5 μM) for 30 min and mounted on
the inverted microscope previously described. A gravity-driven
perfusion set-up in conjunction with an aspirator was used to gently
change solution without disturbing endothelial cell patches. Cells were
imaged at 10 fps with PSS being gravity-perfused to provide a
baseline recording of 5000 frames (8 min 20 s). Without stopping
perfusion, ACh (50 nM in PSS + 2 mM NaPy) was then administered
for a further 5000 frames, to ensure endothelial cells within the patch
were fully responsive. Patches were washed with PSS + 2 mM NaPy
for a further 5,000 frames, and then caffeine (10 mM in PSS + 2 mM
NaPy) was administered for a further 5,000 frames and the
corresponding Ca2+ signals acquired.
2.10 | Endothelial patch image analysis
Cells were manually identified, and the F/F0 intracellular Ca
2+ levels
calculated. Data were smoothed over 20 data points and the resulting
traces plotted in MATLAB R2018a (The Mathworks Inc, Natick,
Massachusetts, United States; RRID:SCR_001622).
2.11 | FKBP12 immunocytochemistry
The antibody-based procedures used in this study comply with the
recommendations made by the British Journal of Pharmacology
(Alexander et al., 2018). Second-order mesenteric arteries were
dissected and then pinned out on Sylgard bases in six well plates,
fixed with freshly prepared paraformaldehyde (4%), and left overnight
at 4C. All washes were performed for 5 min unless otherwise stated.
After washing three times with 0.1-M glycine, preparations were
washed three times in PBS and permeabilized for 10 min in 0.2%
Triton-X100. Preparations were then washed three times in PBS,
three times in an antibody wash solution (20× SSC, 0.05%
Triton-X100 in ddH20), and blocked in 5% BSA for 1 hr. Preparations
were next washed three times in antibody wash solution and
incubated overnight at 4C either with the primary antibody
(Abcam rabbit polyclonal Anti-FKBP12, Ab2918) or without it (for a
no-primary control) in antibody buffer (20× SSC, 2% donkey serum,
1% BSA, 0.05% Triton X-100, 0.02% sodium azide in ddH20).
Preparations were then washed three times in antibody wash solution
and incubated with a secondary antibody (Invitrogen AF488 donkey
anti-rabbit, A-21206) in antibody buffer for 1 hr at room temperature
then washed three times in antibody wash solution. Immediately prior
to imaging, preparations were incubated in 4-nM DAPI for 5 min and
washed with PBS. A Nikon Eclipse FNI upright microscopy body with
a Nikon Fluor 40× 0.8 NA water immersion objective lens, illuminated
by a pE-4000 CoolLED system at 365 and 470 nm, was used to image
the preparations; 100 images were acquired and an average image
intensity projection taken using Fiji (Schindelin et al., 2012).
2.12 | Data and statistical analysis
The data and statistical analysis comply with the recommendations
of the British Journal of Pharmacology on experimental design and
analysis in pharmacology (Curtis et al., 2018). Biological replicates are
presented as graphical summary data. These were averaged, paired
responses in arteries from ≥5 different animals. Mean values are
shown as means ± SEM. Technical replicates are the three repeat
measurements of each conditions. Raw peak F/F0 responses were log
transformed to ensure normal distribution of the data, analysed
statistically using either a paired Student's t test or a two-way ANOVA
with Tukey's multiple comparisons test on Prism, version 6.0 (GraphPad,
La Jolla, CA, USA; RRID:SCR_005375), and the means back-transformed
for data presentation. P < .05 was considered statistically significant.
2.13 | Materials
Ins(1,4,5)P3-caged IP3 was obtained from SiChem. Cal-520/AM,
anti-FKBP12, and donkey serum were obtained from Abcam
(Cambridge, MA, USA). Pluronic F-127 was obtained from Invitrogen
(Carlsbad, CA, USA). AF488 donkey anti-rabbit was obtained from
Invitrogen. FK506, rapamycin, cypermethrin, okadaic acid, caffeine,
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2-APB, and all other chemicals were obtained from Sigma-Aldrich
(St. Louis, MO, USA). All solutions were freshly prepared each day.
2.14 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Fabbro
et al., 2019a; Alexander, Mathie et al., 2019b).
3 | RESULTS
3.1 | Ca2+ release from the intracellular store
Ca2+ release from intracellular stores within endothelial cells
may occur via IP3R or RyR, or both. As a first step in determining
the contribution of IP3R and RyR, cells were activated with the
IP3-mobilizing agonist ACh (50 nM; Figure 1a; Video S1). ACh evoked
reproducible increases in Ca2+ (Figure 1a(i–iii)). To verify that
ACh-evoked Ca2+ increases were IP3-dependent, arteries were
incubated with the IP3R antagonist 2-APB (500 μM) for 10 min and
ACh reapplied to the same preparation (Figure 1b). In the presence of
F IGURE 1 ACh evokes reproducible Ca2+ increases that are blocked by the IP3R antagonist 2-APB. (a) Reproducible ACh-evoked (50 nM,
1.5 mlmin−1) Ca2+ signalling in ~100 cells, (i) represented as average intensity (grayscale) and contrast-matched images of Ca2+ activity (JET LUT) for
each repeat ACh application (15min apart). (ii) Individual F/F0 Ca
2+ traces from each cell are shown, with traces coloured according to intensity of
response from red to blue, and the average signal overlaid in black. The average signal for each repeat is plotted in the graph on the left. ACh
activation is indicated by bars above the traces. (iii) Summary data of the mean F/F0 value from each cell, the average number of oscillation peaks per
cell, and themean duration of the responses for each of the three repeats. The colour of each point corresponds to the density of the plotted points.
(b) Representative contrast-matched (JET LUT) images of ACh-evoked Ca2+ activity (i) in the absence or (ii) presence of the IP3R antagonist 2-APB
(500 μM, 10-min incubation). The corresponding F/F0 traces are shown (average signal overlaid in black) (iii) in the absence or (iv) presence of 2-APB,
with the ACh application indicated with a bar above the trace. Scale bars = 50 μm [Colour figure can be viewed at wileyonlinelibrary.com]
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2-APB, ACh no longer evoked Ca2+ increases (Figure 1b). To confirm
that 2-APB (500 μM for 10 min) was not cytotoxic, preparations were
subsequently stained with propidium iodide (1.5 μM) then washed for
>30mins and restimulated with ACh (Figure S2). After the protocol,
cells were largely unaffected (one cell death occurred in a field of
~300 cells, yellow arrow, Figure S2B). The Ca2+ response to ACh was
eliminated in the presence of 2-APB but was partly restored after PSS
washing (Figure S2A–D).
To confirm the efficacy of IP3 in evoking Ca
2+ release, the
inositide was flash-released using a photoactivatable form of
caged-IP3 in a localized group of endothelial cells (Figure 2a, region
highlighted by yellow circle; Video S2). Photo-release of caged-IP3
generated rapid, reproducible Ca2+ transients in the endothelial cells
targeted for photolysis. Ca2+ release evoked by photolysis of caged
IP3 was also blocked by 2-APB (Figure 2b).
3.2 | RyR does not contribute to Ca2+ signals
arising from the internal store
To determine the extent to which RyRs contribute to Ca2+ release
from the endothelial intracellular store, the potent RyR activator,
caffeine (10 mM) was applied. While the artery rapidly responded by
contracting, as the smooth muscle cells activated, there was no
F IGURE 2 Photo-uncaged IP3 evokes reproducible Ca
2+ responses that are blocked by the IP3R antagonist 2-APB. (a) Reproducible IP3-
activated (5 μM) Ca2+ signalling in ~30 endothelial cells, represented as average intensity (grayscale; left. Yellow circle represents the subsequent
uncaging region) and contrast-matched (JET LUT) images of Ca2+ activity each repeat application (15 min apart). (ii) Individual F/F0 Ca
2+ traces
from each cell are shown, with traces coloured according to intensity of response from red to blue, and the average signal overlaid in black. The
average signal for each repeat is plotted in the graph on the left. Activation is indicated by an arrow above the image. Only cells in which IP3 was
directly uncaged were analysed. (iii) Summary data on the average F/F0 value from each cell, the average number of oscillation peaks per cell, and
the mean duration of the responses for the three repeats. The colour of each point corresponds to the density of the plotted points.
(b) Representative contrast-matched JET LUT images of IP3-evoked Ca
2+ activity (i) in the absence or (ii) presence of the IP3R antagonist 2-APB
(500 μM, 10-min incubation). The corresponding F/F0 traces are shown (average signal overlaid in black) (iii) in the absence or (iv) presence of
2-APB, with the stimulus indicated by an arrow. Scale bars = 50 μm [Colour figure can be viewed at wileyonlinelibrary.com]
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endothelial Ca2+ signal evoked by caffeine (Figure 3a; Video S3). A
quantitative analysis of caffeine-induced signal intensity was not
possible because of the arterial contraction which moved cell posi-
tions, so aortic endothelial patches were dissociated from smooth
muscle cells and imaged (Figure 3b). Endothelial patches were imaged
first to obtain a baseline recording (8 min) in PSS flow. Next ACh
(1 μM, 8 min) was applied to the endothelial patches followed by a
wash period (20-min PSS) and finally caffeine (10 mM; 8 min;
Figure 3b(i–ii); Video S4). A representative image of a patch is shown
in Figure 3b(ii), and the corresponding F/F0 traces of the highlighted
cell is plotted in Figure 3b(iii). The endothelial cell showed no
response to PSS flow but had a substantial Ca2+ response to ACh. As
in the intact artery, there was no Ca2+ response to caffeine. On
average, over five biological repeats, 96% endothelial cells analysed
responded to ACh, while only 16% were active during caffeine
perfusion, which was lower than the number of cells expected from
F IGURE 3 RyR do not contribute to endothelial cell Ca2+ release. (a) Representative images of endothelial Ca2+ levels in intact mesenteric
arteries using the en face preparation. Caffeine (10 mM) evokes a substantial transient contraction of the artery. Endothelial Ca2+ images are
shown at rest (baseline), after the maximum vessel caffeine-evoked contraction, and after the artery returned to its initial diameter (full
relaxation). All images are contrast-level matched. The endothelial image after the maximum contraction appears brighter because of the vessel
contraction squeezing the cells so that more indicator is present in the same area; see also Video S3. Scale bar = 50 μm. (b) (i) A schematic
representation of the experimental protocol showing the periods of recording during each experiment. (b) (ii) Ca2+ images in isolated aortic
endothelial cell patches in response to basal perfusion (control, left), perfusion with ACh (1 μM; middle), and after caffeine (10 mM; right; scale
bar = 10 μm). (iii) F/F0 Ca2+ traces from the cells indicated in (ii). (iv) Paired summary data showing the effect of each agonist on the percentage of
cells exhibiting Ca2+ activity. In this analysis, any activity is counted as a responding cell, and the results show that caffeine inhibits basal Ca2+
activity (n = 5, overlapping data points appear as single circles; * P < .05, significantly different as indicated) [Colour figure can be viewed at
wileyonlinelibrary.com]
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baseline spontaneous activity (on average 48% cells; Figure 3b; iv).
The higher percentage of cells showing basal activity is likely to be a
consequence of the smaller number of cells in the endothelial patches
(when compared to the intact artery), and the use of sodium pyruvate
in the PSS which leads to a greater basal Ca2+ response to shear stress
(Wilson, Lee, & McCarron, 2016). The lower number of cells showing
baseline spontaneous Ca2+ signals in caffeine probably reflects a
caffeine-induced inhibition of IP3R activity that generates the
spontaneous activity (Brown, Sayers, Kirk, Michell, & Michelangeli,
1992; Missiaen, Taylor, & Berridge, 1992; Parker & Ivorra, 1991; Wilson
et al., 2019). These results show that ACh evokes a substantial Ca2+
increase while caffeine does not. Agonists of RyR do not appear to
mediate Ca2+ release from the mesenteric or aortic endothelium.
To confirm that RyRs do not mediate mesenteric endothelial Ca2+
regulation, after a basal ACh (50 nM) stimulation, preparations were
washed and stimulated using ryanodine alone (30 μM). Preparations
were washed and caffeine (10 mM) added to cause the characteristic
artery contraction and relaxation. Ryanodine was then added to the
caffeine-stimulated preparations (Figure 4a–e; ). Practically no
endothelial Ca2+ responses were elicited in response to ryanodine in
the absence (0.05 ± 0.02 AFU; mean values ± SEM) or presence
(0.006 ± 0.003 AFU) of caffeine, when compared with a basal ACh
response (0.3 ± 0.06 AFU). Preparations were washed and again
incubated with ryanodine for 15 min, followed immediately by
ryanodine and caffeine stimulation (0.001 ± 0.001 AFU). Again, no
response was seen in preparations. When caffeine was removed and
ACh (50 nM) added to the ryanodine, a strong Ca2+ response was
elicited (Figure 4b(i–iii); 0.54 ± 0.08 AFU). These experiments
again suggest that RyR do not have a functional role in mesenteric
endothelial Ca2+ regulation.
3.3 | FK506 modulates IP3-evoked Ca
2+ signals by
calcineurin inhibition
In other tissues, FKBP12 has been shown to regulate Ca2+ release
from the internal store. However, very little is known about the role
F IGURE 4 RyR does not contribute to endothelial cell Ca2+ release. (a) Representative, contrast-matched images of endothelial Ca2+ levels in
an intact mesenteric artery using the en face preparation after ACh (50 nM) or ryanodine (30 μM) administration, ryanodine added in the presence
of caffeine (10 mM), caffeine added in the presence of ryanodine, or ACh added in the presence of ryanodine. Images are shown using JET LUT.
Scale bar = 100 μm. (b) Individual F/F0 Ca2+ traces from each cell are shown for each of the above conditions. Traces are coloured according to
intensity of response from red to blue, and the average signal overlaid in black. Reagents present are indicated by a bar above the image.
(c) Average trace for each condition plotted alone. (d) Summary data on the average F/F0 value from each cell for each of the conditions. The
colour of each point corresponds to the density of the plotted points. (e) Average F/F0 value for each biological replicate for each condition. n = 5;
* P < .05, significantly different from baseline ACh recording; all data are matched [Colour figure can be viewed at wileyonlinelibrary.com]
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of FKBP in endothelial cell Ca2+ modulation. To first establish whether
or not FKBP12 is present in endothelial cells, immunohistochemistry
was performed (Figure 5). FKBP12 (green puncta) was present
throughout the endothelial cell cytoplasm (Figure 5a(i–ii)). Staining
was absent in controls that lacked the primary antibody (Figure 5b).
These results confirm the presence of FKBP12 in mesenteric artery
endothelial cells.
FK506 disrupts binding of FKBP to IP3R and may result in “leaky”
channels (Liu et al., 2018) as occurs with RyR (Long et al., 2007).
However, the present results showed no change in basal Ca2+
signalling activity in the presence of FK506 (Figure S3) suggesting no
change in channel “leak.” To further investigate the role FKBP12
plays in endothelial Ca2+ regulation, IP3Rs were stimulated before
and after incubation with FK506 (10 μM). In each experiment, ~100
endothelial cells were studied, and all comparisons were matched
between cells in the same preparation. IP3R activation was achieved
either by flash release of a caged form of IP3 (5 μM) in a localized
group of endothelial cells (Figure 6a) or by ACh (50 nM; 1.5 mlmin−1,
Figure 6b).
FK506 evoked an increase in the Ca2+ transient generated by
each method of IP3R activation (Figure 6i,ii). The peak ΔF/F0
amplitude was significantly increased after FK506 incubation for
IP3-evoked (n = 5, 1.41 ± 0.10 to 1.81 ± 0.20) and ACh-evoked (n = 6,
0.78 ± 0.1 to 0.85 ± 0.1) signals (Figure 6v). Likewise, the average cell
ΔF/F0 (Figure 6iv) increased after FK506 incubation for both IP3 and
ACh stimulation. Analysis of the distribution of Ca2+ oscillations
shows a shift towards a larger number of oscillations after incubation
with FK506 under both types of IP3R stimulation (Figure 6iii).
The FKBP-FK506 complex inhibits calcineurin. To determine
whether or not the FK506-induced increase in Ca2+ store release was
due to inhibition of calcineurin, the inhibitors cypermethrin (10 μM) or
okadaic acid (5 μM) were each used. Ca2+ release (peak ΔF/F0) was
significantly increased after incubation (30 min) with either
cypermethrin (Figure 7v, n = 7, 1.45 ± 0.14 to 1.73 ± 0.14, for IP3
activation in panel a, n = 5, 0.88 ± 0.11 to 1.05 ± 0.12, for ACh
activation in panel b) or okadaic acid (Figure 8v, n = 6, 1.30 ± 0.12 to
1.52 ± 0.17). The increase was also evident in the Ca2+ signal images
(Figures 7a(i), 7b(i), and 8i), the individual F/F0 traces (Figures 7a(ii),
7b(ii), and 8ii), and the average cell ΔF/F0 values (Figures 7a(iv), 7b(iv),
and 8iv). These results suggest that the phosphatase calcineurin limits
IP3R activity.
Significantly, in the presence of cypermethrin, FK506 failed to
increase IP3-mediated Ca
2+ release (Figure 7a(v), n = 7, 1.73 ± 0.14 to
1.90 ± 0.19). After cypermethrin, FK506 also failed to increase
ACh-evoked Ca2+ release (Figure 7b(v), n = 5, 1.05 ± 0.12 to
0.75 ± 0.16). After the phosphatase inhibitor okadaic acid, FK506
significantly reduced IP3-mediated Ca
2+ release (Figure 8v, n = 6,
1.52 ± 0.17 to 1.33 ± 0.19). There was no significant difference in the
number of ACh-activated Ca2+ oscillations after incubation with
FK506 and cypermethrin or okadaic acid (Figures 7a(iii), 7b(iii), and
F IGURE 5 FKBP12 is present in mesenteric arterial endothelial cells. Representative en face mesenteric arterial preparations stained with
(a) an anti-FKBP12 antibody (green) or (b) with a no-primary antibody control (non-specific binding). Images are shown (i) merged, (ii) the 488-nm
channel alone, or (ii) the 405-nm DAPI channel alone. Each image is an average projection of 100 images, and all images are contrast matched.
Scale bars = 50 μm. Representative of three separate experiments [Colour figure can be viewed at wileyonlinelibrary.com]
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8iii). These results suggest that the increase in IP3-evoked Ca
2+
release generated by FK506 is mediated by an effect of the drug on
calcineurin rather than FKBP modulation itself.
3.4 | Rapamycin does not alter IP3-evoked Ca
2+
signals
Rapamycin also disrupts FKBP12 binding to IP3R but, unlike FK506,
does not inhibit calcineurin. Rapamycin did not alter IP3-evoked Ca
2+
release. Ca2+ release was stimulated by localized photolysis of caged
IP3 (Figure 9). There was no difference in the peak amplitude of
IP3-evoked F/F0 amplitude (Figure 9i–v, n = 5, 1.45 ± 0.25 to
1.48 ± 0.23), or in the characteristics of the subsequent Ca2+
oscillatory profile (Figure 9iii) after rapamycin (10 μM, 30 min).
Together, these results suggest FKBP is not directly involved in
endothelial IP3R regulation.
4 | DISCUSSION
The immunosuppressant drugs FK506 and rapamycin are routinely
used after organ transplantation and are effective at lowering organ
rejection, though a major side effect of the treatment is hypertension
(Chiasson et al., 2011; De Lima et al., 1999; Reis et al., 2009).
Increased vascular resistance (Spencer, Goa, & Gillis, 1997; Textor
et al., 1993) as a result of altered endothelial function and decreased
production of the vasodilator NO appears central to the development
of hypertension (De Lima et al., 1999; Takeda et al., 1999). However,
while immunosuppressant-induced hypertension coupled with
endothelial dysfunction is significant in the systemic circulation, this
may not be the case in the pulmonary circulation. Rather than
being induced, pulmonary hypertension is suppressed by rapamycin
(Houssaini et al., 2013) as a result of decreased smooth muscle
proliferation. This finding points to significant differences in the
F IGURE 6 FK506 increases endothelial IP3- and ACh-evoked Ca
2+ release. Ca2+ release was stimulated via either (a) localized photolysis of
caged IP3 (5 μM) or (b) ACh (50 nM; flow at 1.5 mlmin−1). Only cells within which IP3 was directly uncaged were analysed; therefore, more cells
were analysed per artery for ACh stimulation. (i) Average intensity images of the endothelial cell field at baseline (grayscale, yellow circle
represents the subsequent uncaging region) and representative contrast-matched images (Jet LUT) of paired endothelial cell Ca2+ levels after IP3
or ACh stimulation under control conditions or after 30-min incubation with FK506 (10 μM). Scale bars = 50 μm. (ii) Representative individual F/
F0 traces from 10-s recordings after stimulation for a single cell are shown. Control (blue) and FK506-treated (green) traces are compared for each
technical replicate within an experiment. (iii) Fitted curves for histograms illustrating the spread of the average number of oscillations per cell for
control and FK506-incubated conditions across all technical and biological repeats. (iv) Summary data for the average F/F0 value from each cell
(colour corresponds to the density of the plotted points). Data are technical repeats from a single experiment, with control and FK506-incubated
recordings indicated with a blue or green bar beneath the data respectively. (v) Peak F/F0 signals averaged for each cell and across three technical
replicates for each biological repeat, compared between control and FK506. Each biological replicate is shown, with the average highlighted in
bold. n = 5,6; * P < .05, significantly different as indicated [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 7 Cypermethrin increases Ca2+ release and blocks FK506-induced increase in IP3- and ACh-evoked Ca
2+ release. Ca2+ release was
stimulated by either localized photolysis of caged IP3 (5 μM) (a) or (b) ACh (50 nM; flow at 1.5 mlmin−1). Only cells within which IP3 was directly
uncaged were analysed; therefore, more cells were analysed per artery for ACh stimulation. (i) Average intensity images of the endothelial cell
field at baseline (grayscale, yellow circle represents the subsequent uncaging region) and representative contrast-matched images (Jet LUT) of
paired endothelial cell Ca2+ levels after IP3 or ACh stimulation under control, cypermethrin (CyperM; 10 μM, 30-min incubation), or
cypermethrin-FK506 (10 μM of each drug, 30-min incubation) conditions. Scale bars = 50 μm. (ii) Representative individual F/F0 traces from 10-s
recordings after stimulation for a single cell are shown. Control, cypermethrin and both cypermethrin- and FK506-treated traces are compared for
each technical replicate within an experiment. (iii) Fitted curves for histograms illustrating the spread of the average number of oscillations per cell
for control, cypermethrin-incubated and cypermethrin-FK506-incubated conditions, across all technical and biological repeats. (iv) Summary data
for the average F/F0 value from each cell (colour corresponds to the density of the plotted points). Data are technical repeats from a single
experiment, with control, cypermethrin-incubated, and cypermethrin- and FK506-incubated recordings indicated with a blue, pink, or green bar
beneath the data respectively. (v) Peak F/F0 signals averaged for each cell and across three technical replicates for each biological repeat,
compared between control, cypermethrin and both FK506 and cypermethrin incubation. Each biological replicate is shown, with the average
highlighted in bold. (n = 5 for IP3, n = 7 for ACh; *P < .05, significantly different as indicated) [Colour figure can be viewed at wileyonlinelibrary.
com]
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pulmonary and systemic circulations and that the antiproliferative
effects of rapamycin are insufficient to offset other effects of the drug
in generating systemic hypertension.
The cellular mechanisms that give rise to decreased NO
production and endothelial dysfunction evoked by FK506 and
rapamycin are not fully understood though alterations in normal Ca2+
handling may be key. In other cell types, FK506 and rapamycin exert
multiple effects on cellular function by modulating Ca2+ signalling.
FK506 and rapamycin alter binding of FKBP to RyR and IP3R which
may regulate channel activity. FK506-FKBP additionally inhibits the
phosphatase calcineurin. Here, in native endothelial cells on intact
blood vessels, we explored the possibility that FKBP binding to IP3R
and RyR may regulate Ca2+ signalling and thus contribute to the
effects of the immunosuppressants on vascular function.
Our results suggest endothelial IP3R activity is not directly
modulated by FKBP. In support, FKBP modulation with rapamycin did
not alter IP3-evoked Ca
2+ release. On the other hand, FK506 did
increase IP3-evoked Ca
2+ release, but that modulation was likely to be
indirect and exerted via inhibition of calcineurin. Okadaic acid and
cypermethrin, known inhibitors of calcineurin, also increased
IP3-evoked Ca
2+ release. Significantly, calcineurin inhibitors blocked
FK506-evoked Ca2+ increases, and FK506 decreased IP3-evoked Ca
2+
release in the presence of okadaic acid. This finding raises the
possibility that FK506 by itself may inhibit IP3R in the endothelium,
an effect that is normally offset by potentiation of Ca2+ release,
mediated by inhibition of calcineurin. The precise mechanisms by
which calcineurin inhibition potentiates IP3-evoked Ca
2+ release is not
clear but presumably arises from a direct or indirect influence of a
dephosphorylation event on IP3R. Interestingly, caged IP3 and ACh
elicited a different response to dual cypermethrin-FK506 incubation,
though the reasons behind this remain unclear. Nor are FK506 and
rapamycin likely to mediate their effects on the endothelium via RyR.
The RyR activator caffeine failed to evoke Ca2+ changes in the
endothelium, and ryanodine itself did not alter Ca2+ release in
pre-activated preparations, suggesting that RyR is not functional in
the native endothelium. Together these results suggest that FKBPs do
not regulate Ca2+ release via IP3R or RyR in endothelial cells and that
the hypertensive effects of FK506 and rapamycin may be exerted at
sites separate from the documented effects of these two drugs on
FKBP-mediated Ca2+ release from IP3R or RyR.
F IGURE 8 Okadaic acid increases Ca2+ release and blocks FK506-induced increase in endothelial IP3- and ACh-evoked Ca
2+ release. Ca2+
release was stimulated via localized photolysis of caged IP3 (5 μM). (i) Average intensity images of paired endothelial cell field at baseline
(grayscale, yellow circle represents the subsequent uncaging region) and representative contrast-matched images (Jet LUT) of the endothelial cell
Ca2+ levels after IP3 stimulation under control, okadaic acid (OkA; 10 μM, 30 min incubation), or okadaic acid-FK506 (10 μM each drug, 30-min
incubation) conditions. Scale bar = 50 μm. (ii) Representative individual F/F0 traces from 10-s recordings after stimulation for a single cell are
shown. Control, okadaic acid and both okadaic acid- and FK506-treated traces are compared for each technical replicate within an experiment.
(iii) Fitted curves for histograms illustrating the spread of the average number of oscillations per cell for control, okadaic acid and okadaic acid-
FK506, across all technical and biological repeats. (iv) Summary data for the average F/F0 value from each cell (colour corresponds to the density
of the plotted points). Data are technical replicates from a single experiment, with control, okadaic acid-incubated, and okadaic acid- and FK506-
incubated recordings indicated with a blue, pink, or green bar beneath the data respectively. (v) Peak F/F0 signals averaged for each cell and
across three technical replicates for each biological repeat, compared between control, okadaic acid and both FK506 and okadaic acid conditions.
Each biological replicate is shown, with the average highlighted in bold. n = 5, *; P < .05, significantly different as indicated [Colour figure can be
viewed at wileyonlinelibrary.com]
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While the present results suggest that FKBP modulation by
FK506 and rapamycin do not alter Ca2+ release, several studies show
changes in endothelial function evoked by the immunosuppressants.
FK506 results in endothelial tube malformation in cell cultures
(Eguchi et al., 2013; Wilasrusmee et al., 2003) and a reduced
endothelium-dependent relaxation in mouse aorta (Chiasson et al.,
2011; Cook et al., 2009 ; Long et al., 2007). As relaxation in response
to the smooth muscle activator sodium nitroprusside was reported to
be normal (Chiasson et al., 2011), this suggests that FK506 acted via
the endothelium rather than smooth muscle. Furthermore, FK506 and
rapamycin each decreased NO production in mouse and rat aorta
(Long et al., 2007; Takeda et al., 1999). In rat mesenteric artery,
FK506 also increased the production of the endothelium-derived
smooth muscle contractile agent endothelin (Takeda et al., 1999).
These studies suggest that the immunosuppressants evoke changes
in endothelial function, which could underlie the development of
vascular dysfunction and hypertension.
However, in other studies, more widespread effects of the drugs
have been reported. In human and rat resistance arteries, in vitro
exposure to FK506 for 24hr increased sensitivity to noradrenaline
and impaired endothelium-dependent relaxation to ACh (De Lima
et al., 1999). However, endothelium-independent relaxation to
sodium nitroprusside was also reduced (De Lima et al., 1999),
suggesting that both endothelial and smooth muscle function may
be affected by FK506. In the same study (De Lima et al., 1999),
rats given FK506 chronically for 8 days showed a reduced artery
sensitivity to noradrenaline and a normal endothelium-dependent
relaxation (De Lima et al., 1999). These results highlight
time-dependent and complex changes in vascular responses evoked
by this immunosuppressant. FK506 itself was found to evoke smooth
muscle contraction in rat renal arteries (Schwertfeger et al., 2001) and
to increase the sensitivity to contractile activation (noradrenaline) in
rat mesenteric and human subcutaneous arteries (De Lima et al.,
1999; Schwertfeger et al., 2001). However, the drug did not to induce
contraction in bovine renal, mesenteric, coronary, or carotid arteries
(Epstein et al., 1998) and inhibited contraction induced by high K+
depolarization and U46619 in porcine coronary artery (Yasutsune
et al., 1999). Collectively, these studies create ambiguity about the
vascular site on which the drugs work—the endothelium, smooth
muscle, both, or neither—to produce hypertension.
F IGURE 9 Rapamycin does not alter endothelial IP3-evoked Ca
2+ release. Ca2+ release was stimulated via localized photolysis of caged IP3
(5 μM) under no flow conditions. (i) Average intensity images of paired endothelial cell field at baseline (grayscale, yellow circle represents the
subsequent uncaging region) and representative contrast-matched images (Jet LUT) of the endothelial cell Ca2+ levels after IP3 stimulation under
control or rapamycin (10 μM, 30 min incubation) conditions. Scale bar = 50 μm. (ii) Representative individual F/F0 traces from 10-s recordings
after stimulation for a single cell are shown. Control (blue) and rapamycin (red) traces are compared for each technical replicate within an
experiment. (iii) Fitted curves for histograms illustrating the spread of the average number of oscillations per cell for control and rapamycin
conditions across all technical and biological repeats. (iv) Summary data for the average F/F0 value from each cell (colour corresponds to the
density of the plotted points). Data are technical replicates from a single experiment, with control and rapamycin recordings indicated with a blue
or red bar beneath the data respectively. (v) Peak F/F0 signals averaged for each cell and across three technical replicates for each biological
repeat, compared between control and rapamycin conditions. Each biological replicate is shown, with the average highlighted in bold. n = 5
[Colour figure can be viewed at wileyonlinelibrary.com]
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The heart of the problem is that it is unclear how FKBP-RyR and
FKBP-IP3R interactions regulate Ca
2+ signalling in endothelial beds
across the body. In cultured mouse aortic endothelial cells, depletion
of FKBP increased intracellular Ca2+ leak via RyR (Cook et al., 2009;
Long et al., 2007). In human cultured aortic endothelial cells,
rapamycin increased intracellular Ca2+ which was prevented by
ryanodine (Habib et al., 2013). However, no change in basal Ca2+
activity, therefore no Ca2+ leak, occurred after FK506 or rapamycin in
the present study. Neither could we detect any caffeine- or
ryanodine-evoked RyR-mediated Ca2+ signals, despite caffeine
effectively evoking smooth muscle contraction in the same tissue.
These results suggest that RyR may not be functional in native aortic
or mesenteric endothelium in intact blood vessels. The reason for the
difference between our results and previous findings (Cook et al.,
2009; Long et al., 2007) is unclear, though it may lie in the changes
undergone by endothelial cells during culture (Cook et al., 2009; Long
et al., 2007). Alternatively, differences of endothelial reactivity to
activators of RyR and FK506 and rapamycin may exist across species,
blood vessel type, diseased state, age, and duration of exposure to the
immunosuppressants. These differences could lead to different results
in Ca2+ dynamics in vascular endothelial cells.
There are no previous reports on the effects of FK506 or
rapamycin on IP3-evoked Ca
2+ release in endothelial cells. The present
findings show that FK506 increased IP3-evoked Ca
2+ release via
inhibition of calcineurin and that modulation of FKBP did not alter
IP3-evoked Ca
2+ release, as shown using rapamycin. To ensure the
effects of FK506 were mediated via IP3R activity rather than the
generation of IP3 or surface receptors generating IP3, we directly
activated IP3R using photolysis of caged IP3. The FK506-evoked
increase in IP3-mediated Ca
2+ release was prevented when the
phosphatase calcineurin was blocked, which inhibited and in the case
of okadaic acid, actually decreased further FK506-mediated Ca2+
release. These findings support the suggestion that FK506 may inhibit
IP3R in endothelial cells by a mechanism that is independent of either
FKBP or calcineurin.
Calcineurin appears to regulate IP3-evoked Ca
2+ release in the
endothelium, potentially by forming part of the FKBP-IP3R channel
complex (Bandyopadhyay, Shin, Ahn, & Kim, 2000; Cameron et al.,
1997; Cameron, Steiner, Roskams, et al., 1995; Cameron, Steiner,
Sabatini, et al., 1995; Shin et al., 2002) as FK506-FKBP inhibits the
phosphatase calcineurin. However, there is also a complex literature
on the contribution of calcineurin to the control of IP3-evoked Ca
2+
release. Calcineurin inhibitors increased ATP-induced Ca2+ release
and IP3R activity in COS-7 cells and cerebellar microsomes
respectively (Bandyopadhyay, Shin, & Kim, 2000; Cameron, Steiner,
Roskams, et al., 1995), and expression of a constitutively active form
of calcineurin inhibited Ca2+ release (Bandyopadhyay, Shin, & Kim,
2000). On the other hand, the calcineurin inhibitors cypermethrin and
okadaic acid did not alter Ca2+ release via either RyR (MacMillan
et al., 2008) or IP3R (Macmillan & McCarron, 2009) in aortic
myocytes. Neither did okadaic acid alter Ca2+ in porcine coronary
artery (Ashizawa et al., 1989; Hirano et al., 1989). Cyclosporin A, a
calcineurin inhibitor, did not alter Ca2+ release in pulmonary (Zheng
et al., 2004) and coronary artery myocytes (Frapier et al., 2001) or SR
[Ca2+] in aortic myocytes (Avdonin et al., 1999). These results suggest
that there is also a complex relationship between calcineurin
and regulation of Ca2+ release in the endothelium presumably as a
result of the nature of the kinases that are active in cells, the
phosphorylation/dephosphorylation status of IP3R, and the balance
of activation and inhibition of the IP3 receptor.
In summary, the mechanisms underlying the immunosuppressant-
mediated hypertension and endothelial dysfunction in organ
transplant patients remain unclear. Hypertension induced by genetic
deletion of FKBP12.6 in mice is consistent with a role for FKBPs in
the process (Long et al., 2007). Previous studies suggest that FK506
and rapamycin may exert vascular effects through altered Ca2+
signalling mediated by displacement of FKBP from IP3R or through
FK506-induced inhibition of calcineurin. The present findings show
that rapamycin had no effect on IP3-mediated Ca
2+ release and that
the increase in FK506-mediated Ca2+ release was due to
FK506-FKBP calcineurin inhibition. Calcineurin inhibition also
prevented FK506-mediated IP3-evoked Ca
2+ release. While FK506
and rapamycin share the common side effect of evoking hypertension
in patients, these immunosuppressants do not share a common effect
on endothelial IP3-evoked Ca
2+ release. This raises the possibility that
modulation of Ca2+ release may not be the only factor contributing to
immunosuppressant drug-induced hypertension. FK506 is also known
to induce endothelial dysfunction through attenuation of Akt and
ERK1/2 independently of calcineurin inhibition (Eguchi et al., 2013).
Other FKBPs may also be the target of the drugs. FKBP51 and
FKBP52 regulate steroid receptor signalling and store operated Ca2+
entry and some TRP channels (Hamilton et al., 2018; Kadeba et al.,
2013; Sinkins, Goel, Estacion, & Schilling, 2004) to modulate cell
function. The present findings suggest that rapamycin and FKBP do
not modulate Ca2+ release. However, IP3-mediated Ca
2+ release may
be modulated (a) by FK506 via the phosphatase calcineurin to
increase Ca2+ release, and (b) by FK506 directly inhibiting IP3R.
DECLARATION OF TRANSPARENCY AND SCIENTIFIC
RIGOUR
This Declaration acknowledges that this paper adheres to the
principles for transparent reporting and scientific rigour of preclinical
research as stated in the BJP guidelines for Design & Analysis,
Immunoblotting and Immunochemistry, and Anion, and as recommended
by funding agencies, publishers and other organisations engaged with
supporting research..
ACKNOWLEDGEMENTS
This work was funded by the Wellcome Trust (202924/Z/16/Z and
204682/Z/16/Z) and the British Heart Foundation (PG/16/54/32230
and PG16/82/32439), whose support is gratefully acknowledged.
The authors would like to thank Margaret MacDonald for her
excellent technical support.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
BUCKLEY ET AL. 15
AUTHOR CONTRIBUTIONS
C.B., C.W., and J.G.M. developed the concept. C.B. performed the
experiments. C.B. and J.G.M. drafted the manuscript. C.B. C.W., and
J.G.M. edited the manuscript. C.W. and J.G.M. sourced funding.




John G. McCarron https://orcid.org/0000-0002-3302-3984
REFERENCES
Abizaid, A. (2007). Sirolimus-eluting coronary stents: A review. Vascular
Health and Risk Management, 3(2), 191–201.
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A.,
Veale, E. L., … CGTP Collaborators (2019a). The Concise Guide
to PHARMACOLOGY 2019/20: Enzymes. British Journal of
Pharmacology, 176, S297–S396. https://doi.org/10.1111/bph.14752
Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J.,
Kelly, E., … CGTP Collaborators (2019b). The Concise Guide to
PHARMACOLOGY 2019/20: Ion channels. British Journal of
Pharmacology, 176, S142–S228. https://doi.org/10.1111/bph.14749
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G.,
George, C. H., Stanford, S. C., … Ahluwalia, A. (2018). Goals and
practicalities of immunoblotting and immunohistochemistry: A guide
for submission to the British Journal of Pharmacology. British Journal
of Pharmacology, 175(3), 407–411.
Ashizawa, N., Kobayashi, F., Tanaka, Y., & Nakayama, K. (1989). Relaxing
action of okadaic acid, a black sponge toxin on the arterial smooth
muscle. Biochemical and Biophysical Research Communications, 162(3),
971–976.
Avdonin, P. V., Cottet-Maire, F., Afanasjeva, G. V., Loktionova, S. A.,
Lhote, P., & Ruegg, U. T. (1999). Cyclosporine A up-regulates
angiotensin II receptors and calcium responses in human vascular
smooth muscle cells. Kidney International, 55(6), 2407–2414.
Bandyopadhyay, A., Shin, D. W., Ahn, J. O., & Kim, D. H. (2000).
Calcineurin regulates ryanodine receptor/Ca2+-release channels in rat
heart. The Biochemical Journal, 352(Pt 1), 61–70.
Bandyopadhyay, A., Shin, D. W., & Kim, D. H. (2000). Regulation of
ATP-induced calcium release in COS-7 cells by calcineurin.
The Biochemical Journal, 348(Pt 1), 173–181.
Barg, S., Copello, J. A., & Fleischer, S. (1997). Different interactions of
cardiac and skeletal muscle ryanodine receptors with FK-506 binding
protein isoforms. The American Journal of Physiology, 272(5 Pt 1),
C1726–C1733.
Bielefeldt, K., Sharma, R. V., Whiteis, C., Yedidag, E., & Abboud, F. M.
(1997). Tacrolimus (FK506) modulates calcium release and contractility
of intestinal smooth muscle. Cell Calcium, 22(6), 507–514.
Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A.,
Burakoff, S. J., Crabtree, G., & Schreiber, S. L. (1990). Two distinct
signal transmission pathways in T lymphocytes are inhibited by
complexes formed between an immunophilin and either FK506 or
rapamycin. Proceedings of the National Academy of Sciences of the
United States of America, 87(23), 9231–9235.
Boehning, D., & Joseph, S. K. (2000). Functional properties of recombinant
type I and type III inositol 1, 4,5-trisphosphate receptor isoforms
expressed in COS-7 cells. The Journal of Biological Chemistry, 275(28),
21492–21499.
Bradley, K. N., Currie, S., MacMillan, D., Muir, T. C., & McCarron, J. G.
(2003). Cyclic ADP-ribose increases Ca2+ removal in smooth muscle.
Journal of Cell Science, 116(Pt 21), 4291–4306.
Brillantes, A. B., Ondrias, K., Scott, A., Kobrinsky, E., Ondriasova, E.,
Moschella, M. C., … Marks, A. R. (1994). Stabilization of calcium
release channel (ryanodine receptor) function by FK506-binding
protein. Cell, 77(4), 513–523.
Brown, G. R., Sayers, L. G., Kirk, C. J., Michell, R. H., & Michelangeli, F.
(1992). The opening of the inositol 1,4,5-trisphosphate-sensitive Ca2+
channel in rat cerebellum is inhibited by caffeine. The Biochemical
Journal, 282(Pt 2), 309–312.
Bultynck, G., De Smet, P., Rossi, D., Callewaert, G., Missiaen, L.,
Sorrentino, V., … Parys, J. B. (2001). Characterization and mapping of
the 12 kDa FK506-binding protein (FKBP12)-binding site on
different isoforms of the ryanodine receptor and of the inositol
1,4,5-trisphosphate receptor. The Biochemical Journal, 354(Pt 2),
413–422.
Bultynck, G., De Smet, P., Weidema, A. F., Ver Heyen, M., Maes, K.,
Callewaert, G., … De Smedt, H. (2000). Effects of the
immunosuppressant FK506 on intracellular Ca2+ release and Ca2+
accumulation mechanisms. The Journal of Physiology, 525(Pt 3),
681–693.
Bultynck, G., Rossi, D., Callewaert, G., Missiaen, L., Sorrentino, V.,
Parys, J. B., & de Smedt, H. (2001). The conserved sites for the
FK506-binding proteins in ryanodine receptors and inositol
1,4,5-trisphosphate receptors are structurally and functionally
different. The Journal of Biological Chemistry, 276(50), 47715–47724.
https://doi.org/10.1074/jbc.M106573200
Cameron, A. M., Nucifora, F. C. Jr., Fung, E. T., Livingston, D. J.,
Aldape, R. A., Ross, C. A., & Snyder, S. H. (1997). FKBP12 binds the
inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401)
and anchors calcineurin to this FK506-like domain. The Journal of
Biological Chemistry, 272(44), 27582–27588.
Cameron, A. M., Steiner, J. P., Roskams, A. J., Ali, S. M., Ronnett, G. V., &
Snyder, S. H. (1995). Calcineurin associated with the inositol
1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux.
Cell, 83(3), 463–472. https://doi.org/10.1016/0092-8674(95)90124-8
Cameron, A. M., Steiner, J. P., Sabatini, D. M., Kaplin, A. I.,
Walensky, L. D., & Snyder, S. H. (1995). Immunophilin FK506
binding protein associated with inositol 1,4,5-trisphosphate receptor
modulates calcium flux. Proceedings of the National Academy of
Sciences of the United States of America, 92(5), 1784–1788.
Carmody, M., Mackrill, J. J., Sorrentino, V., & O'Neill, C. (2001). FKBP12
associates tightly with the skeletal muscle type 1 ryanodine
receptor, but not with other intracellular calcium release
channels. FEBS Letters, 505(1), 97–102. https://doi.org/10.1016/
s0014-5793(01)02787-9
Chiasson, V. L., Talreja, D., Young, K. J., Chatterjee, P.,
Banes-Berceli, A. K., & Mitchell, B. M. (2011). FK506 binding protein
12 deficiency in endothelial and hematopoietic cells decreases
regulatory T cells and causes hypertension. Hypertension, 57(6),
1167–1175. https://doi.org/10.1161/HYPERTENSIONAHA.110.
162917
Cook, L. G., Chiasson, V. L., Long, C., Wu, G. Y., & Mitchell, B. M. (2009).
Tacrolimus reduces nitric oxide synthase function by binding to FKBP
rather than by its calcineurin effect. Kidney International, 75(7),
719–726.
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H.,
Giembycz, M. A., … Ahluwalia, A. (2018). Experimental design and
analysis and their reporting II: Updated and simplified guidance for
authors and peer reviewers. British Journal of Pharmacology, 175(7),
987–993. https://doi.org/10.1111/bph.14153
Dargan, S. L., Lea, E. J., & Dawson, A. P. (2002). Modulation of type-1
Ins(1,4,5)P3 receptor channels by the FK506-binding protein, FKBP12.
The Biochemical Journal, 361(Pt 2), 401–407.
De Lima, J. J., Xue, H., Coburn, L., Andoh, T. F., McCarron, D. A.,
Bennett, W. M., & Roullet, J. B. (1999). Effects of FK506 in rat and
human resistance arteries. Kidney International, 55(4), 1518–1527.
16 BUCKLEY ET AL.
duBell, W. H., Wright, P. A., Lederer, W. J., & Rogers, T. B. (1997). Effect
of the immunosupressant FK506 on excitation-contraction coupling
and outward K+ currents in rat ventricular myocytes. The Journal of
Physiology, 501(Pt 3), 509–516.
Edelstein, A. D., Tsuchida, M. A., Amodaj, N., Pinkard, H., Vale, R. D., &
Stuurman, N. (2014). Advanced methods of microscope control using
μManager software. Journal of Biological Methods, 1(2), e10.
Eguchi, R., Kubo, S., Ohta, T., Kunimasa, K., Okada, M., Tamaki, H., …
Ogawa, H. (2013). FK506 induces endothelial dysfunction through
attenuation of Akt and ERK1/2 independently of calcineurin inhibition
and the caspase pathway. Cellular Signalling, 25(9), 1731–1738.
Epstein, A., Beall, A., Wynn, J., Mulloy, L., & Brophy, C. M. (1998).
Cyclosporine, but not FK506, selectively induces renal and coronary
artery smooth muscle contraction. Surgery, 123(4), 456–460.
Feletou, M. (2011). The endothelium: Part 1: Multiple functions of the
endothelial cells-focus on endothelium-derived vasoactive mediators.
San Rafael, Morgan & Claypool Life Sciences(CA).
Frapier, J. M., Choby, C., Mangoni, M. E., Nargeot, J., Albat, B., &
Richard, S. (2001). Cyclosporin A increases basal intracellular calcium
and calcium responses to endothelin and vasopressin in human
coronary myocytes. FEBS Letters, 493(1), 57–62.
Guerini, D. (1997). Calcineurin: Not just a simple protein phosphatase.
Biochemical and Biophysical Research Communications, 235(2),
271–275.
Habib, A., Karmali, V., Polavarapu, R., Akahori, H., Cheng, Q., Pachura, K.,
… Finn, A. V. (2013). Sirolimus-FKBP12.6 impairs endothelial barrier
function through protein kinase C-α activation and disruption of the
p120-vascular endothelial cadherin interaction. Arteriosclerosis,
Thrombosis, and Vascular Biology, 33(10), 2425–2431.
Hamilton, C. L., Kadeba, P. I., Vasauskas, A. A., Solodushko, V.,
McClinton, A. K., Alexeyev, M., … Cioffi, D. L. (2018). Protective role
of FKBP51 in calcium entry-induced endothelial barrier disruption.
Pulmonary Circulation, 8(1), 2045893217749987.
Harding, M. W., Galat, A., Uehling, D. E., & Schreiber, S. L. (1989).
A receptor for the immunosuppressant FK506 is a cis-trans
peptidyl-prolyl isomerase. Nature, 341(6244), 758–760. https://doi.
org/10.1038/341758a0
Hepworth, T. J., Lawrie, A. M., & Simpson, A. W. (1997). Okadaic acid
induces the release of Ca2+ from intracellular stores in ECV304
endothelial cells. Cell Calcium, 21(6), 461–467. https://doi.org/
10.1016/s0143-4160(97)90057-9
Hirano, K., Kanaide, H., & Nakamura, M. (1989). Effects of okadaic acid on
cytosolic calcium concentrations and on contractions of the porcine
coronary artery. British Journal of Pharmacology, 98(4), 1261–1266.
https://doi.org/10.1111/j.1476-5381.1989.tb12672.x
Houssaini, A., Abid, S., Mouraret, N., Wan, F., Rideau, D., Saker, M., …
Adnot, S. (2013). Rapamycin reverses pulmonary artery smooth muscle
cell proliferation in pulmonary hypertension. American Journal of
Respiratory Cell and Molecular Biology, 48(5), 568–577. https://doi.org/
10.1165/rcmb.2012-0429OC
Jeanmart, H., Malo, O., Carrier, M., Nickner, C., Desjardins, N., &
Perrault, L. P. (2002). Comparative study of cyclosporine and
tacrolimus vs newer immunosuppressants mycophenolate mofetil and
rapamycin on coronary endothelial function. The Journal of Heart and
Lung Transplantation: The Official Publication of the International Society
for Heart Transplantation, 21(9), 990–998.
Ji, G., Feldman, M. E., Greene, K. S., Sorrentino, V., Xin, H. B., &
Kotlikoff, M. I. (2004). RYR2 proteins contribute to the formation of
Ca2+ sparks in smooth muscle. The Journal of General Physiology,
123(4), 377–386. https://doi.org/10.1085/jgp.200308999
Kadeba, P. I., Vasauskas, A. A., Chen, H., Wu, S., Scammell, J. G., &
Cioffi, D. L. (2013). Regulation of store-operated calcium entry by
FK506-binding immunophilins. Cell Calcium, 53(4), 275–285. https://
doi.org/10.1016/j.ceca.2012.12.008
Kaftan, E., Marks, A. R., & Ehrlich, B. E. (1996). Effects of rapamycin on
ryanodine receptor/Ca2+-release channels from cardiac muscle.
Circulation Research, 78(6), 990–997. https://doi.org/10.1161/01.res.
78.6.990
Kanoh, S., Kondo, M., Tamaoki, J., Shirakawa, H., Aoshiba, K., Miyazaki, S.,
… Nagai, A. (1999). Effect of FK506 on ATP-induced intracellular
calcium oscillations in cow tracheal epithelium. The American Journal of
Physiology, 276(6 Pt 1), L891–L899.
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G.
(2010). Animal research: Reporting in vivo experiments: The ARRIVE
guidelines. British Journal of Pharmacology, 160, 1577–1579.
Klee, C. B., Ren, H., & Wang, X. (1998). Regulation of the calmodulin-
stimulated protein phosphatase, calcineurin. The Journal of Biological
Chemistry, 273(22), 13367–13370.
Kolozsvari, B., Bako, E., Becsi, B., Kiss, A., Czikora, A., Toth, A., … Erdődi, F.
(2012). Calcineurin regulates endothelial barrier function by
interaction with and dephosphorylation of myosin phosphatase.
Cardiovascular Research, 96(3), 494–503.
Lemos, P. A., Lee, C. H., Degertekin, M., Saia, F., Tanabe, K.,
Arampatzis, C. A., … Serruys, P. W. (2003). Early outcome after
sirolimus-eluting stent implantation in patients with acute coronary
syndromes: Insights from the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry. Journal of the
American College of Cardiology, 41(11), 2093–2099.
Lindenfeld, J., Miller, G. G., Shakar, S. F., Zolty, R., Lowes, B. D.,
Wolfel, E. E., … Kobashigawa, J. (2004). Drug therapy in the heart
transplant recipient: Part II: Immunosuppressive drugs. Circulation,
110(25), 3858–3865.
Lindenfeld, J., Page, R. L. 2nd, Zolty, R., Shakar, S. F., Levi, M., Lowes, B., …
Miller, G. G. (2005). Drug therapy in the heart transplant recipient:
Part III: Common medical problems. Circulation, 111(1), 113–117.
Liu, J., Albers, M. W., Wandless, T. J., Luan, S., Alberg, D. G., Belshaw, P. J.,
… Schreiber, S. L. (1992). Inhibition of T cell signaling by
immunophilin-ligand complexes correlates with loss of calcineurin
phosphatase activity. Biochemistry, 31(16), 3896–3901.
Liu, J., Farmer, J. D. Jr., Lane, W. S., Friedman, J., Weissman, I., &
Schreiber, S. L. (1991). Calcineurin is a common target of cyclophilin-
cyclosporin A and FKBP-FK506 complexes. Cell, 66(4), 807–815.
Liu, L., Yang, M., Wang, N., Li, L., Chen, Z. J., & Zhang, C. (2018).
New insights of subfertility among transplanted women:
Immunosuppressive drug FK506 leads to calcium leak and oocyte
activation before fertilization. Journal of Cellular Biochemistry, 119(3),
2964–2977. https://doi.org/10.1002/jcb.26510
Long, C., Cook, L. G., Wu, G. Y., & Mitchell, B. M. (2007). Removal of
FKBP12/12.6 from endothelial ryanodine receptors leads to an
intracellular calcium leak and endothelial dysfunction. Arteriosclerosis,
Thrombosis, and Vascular Biology, 27(7), 1580–1586.
MacMillan, D., Currie, S., Bradley, K. N., Muir, T. C., & McCarron, J. G.
(2005). In smooth muscle, FK506-binding protein modulates IP3
receptor-evoked Ca2+ release by mTOR and calcineurin. Journal of Cell
Science, 118, 5443–5451.
MacMillan, D., Currie, S., & McCarron, J. G. (2008). FK506-binding protein
(FKBP12) regulates ryanodine receptor-evoked Ca2+ release in
colonic but not aortic smooth muscle. Cell Calcium, 43(6), 539–549.
https://doi.org/10.1016/j.ceca.2007.09.002
Macmillan, D., & McCarron, J. G. (2009). Regulation by FK506 and
rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular
smooth muscle: The role of FK506 binding proteins and mTOR. British
Journal of Pharmacology, 158, 1112–1120.
Mayrleitner, M., Timerman, A. P., Wiederrecht, G., & Fleischer, S. (1994).
The calcium release channel of sarcoplasmic reticulum is modulated by
FK-506 binding protein: Effect of FKBP-12 on single channel activity
of the skeletal muscle ryanodine receptor. Cell Calcium, 15(2), 99–108.
https://doi.org/10.1016/0143-4160(94)90048-5
BUCKLEY ET AL. 17
McCarron, J. G., Chalmers, S., MacMillan, D., & Olson, M. L. (2010).
Agonist-evoked Ca2+ wave progression requires Ca2+ and IP3. Journal
of Cell Physiology, 244, 334–344.
McGrath, J. C., & Lilley, E. (2015). Implementing guidelines on
reporting research using animals (ARRIVE etc.): New requirements for
publication in BJP. British Journal of Pharmacology, 172(13),
3189–3193.
Missiaen, L., Taylor, C. W., & Berridge, M. J. (1992). Luminal Ca2+
promoting spontaneous Ca2+ release from inositol trisphosphate-
sensitive stores in rat hepatocytes. The Journal of Physiology, 455,
623–640. https://doi.org/10.1113/jphysiol.1992.sp019319
Murayama, T., Oba, T., Katayama, E., Oyamada, H., Oguchi, K.,
Kobayashi, M., … Ogawa, Y. (1999). Further characterization of the
type 3 ryanodine receptor (RyR3) purified from rabbit diaphragm. The
Journal of Biological Chemistry, 274(24), 17297–17308. https://doi.
org/10.1074/jbc.274.24.17297
Olson, M. L., Chalmers, S., & McCarron, J. G. (2012). Mitochondrial
organization and Ca2+ uptake. Biochemical Society Transactions, 40(1),
158–167. https://doi.org/10.1042/BST20110705
Parker, I., & Ivorra, I. (1991). Caffeine inhibits inositol trisphosphate-
mediated liberation of intracellular calcium in Xenopus oocytes. The
Journal of Physiology, 433, 229–240. https://doi.org/10.1113/jphysiol.
1991.sp018423
Reis, F., Parada, B., Teixeira de Lemos, E., Garrido, P., Dias, A., Piloto, N., …
Teixeira, F. (2009). Hypertension induced by immunosuppressive
drugs: A comparative analysis between sirolimus and cyclosporine.
Transplantation Proceedings, 41(3), 868–873.
Scaramello, C. B., Muzi-Filho, H., Zapata-Sudo, G., Sudo, R. T., & Cunha
Vdo, M. (2009). FKBP12 depletion leads to loss of sarcoplasmic
reticulum Ca2+ stores in rat vas deferens. Journal of Pharmacological
Sciences, 109(2), 185–192.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M.,
Pietzsch, T., … Cardona, A. (2012). Fiji: An open-source platform for
biological-image analysis. Nature Methods, 9(7), 676–682.
Schwertfeger, E., Wehrens, J., Oberhauser, V., Katzenwadel, A., &
Rump, L. C. (2001). Contractile effects of tacrolimus in human and rat
isolated renal arteries. Journal of Autonomic Pharmacology, 21(4),
205–210.
Serruys, P. W., Regar, E., & Carter, A. J. (2002). Rapamycin eluting stent:
The onset of a new era in interventional cardiology. Heart, 87(4),
305–307.
Shin, D. W., Pan, Z., Bandyopadhyay, A., Bhat, M. B., Kim, D. H., & Ma, J.
(2002). Ca2+-dependent interaction between FKBP12 and calcineurin
regulates activity of the Ca2+ release channel in skeletal muscle.
Biophysical Journal, 83(5), 2539–2549. https://doi.org/10.1016/
S0006-3495(02)75265-X
Sinkins, W. G., Goel, M., Estacion, M., & Schilling, W. P. (2004). Association
of immunophilins with mammalian TRPC channels. The Journal of
Biological Chemistry, 279(33), 34521–34529.
Spencer, C. M., Goa, K. L., & Gillis, J. C. (1997). Tacrolimus. An update of
its pharmacology and clinical efficacy in the management of organ
transplantation. Drugs, 54(6), 925–975. https://doi.org/10.2165/
00003495-199754060-00009
Takeda, Y., Miyamori, I., Furukawa, K., Inaba, S., & Mabuchi, H. (1999).
Mechanisms of FK 506-induced hypertension in the rat. Hypertension,
33(1), 130–136. https://doi.org/10.1161/01.hyp.33.1.130
Tang, W. X., Chen, Y. F., Zou, A. P., Campbell, W. B., & Li, P. L. (2002).
Role of FKBP12.6 in cADPR-induced activation of reconstituted
ryanodine receptors from arterial smooth muscle. American Journal of
Physiology. Heart and Circulatory Physiology, 282(4), H1304–H1310.
Taylor, D. O., Barr, M. L., Radovancevic, B., Renlund, D. G., Mentzer, R. M.
Jr., Smart, F. W., … VanVeldhuisen, P. (1999). A randomized,
multicenter comparison of tacrolimus and cyclosporine
immunosuppressive regimens in cardiac transplantation: Decreased
hyperlipidemia and hypertension with tacrolimus. The Journal of Heart
and Lung Transplantation: The Official Publication of the International
Society for Heart Transplantation, 18(4), 336–345.
Textor, S. C., Wiesner, R., Wilson, D. J., Porayko, M., Romero, J. C.,
Burnett, J. C. Jr., … Krom, R. A. (1993). Systemic and renal
hemodynamic differences between FK506 and cyclosporine in liver
transplant recipients. Transplantation, 55(6), 1332–1339.
Thrower, E. C., Mobasheri, H., Dargan, S., Marius, P., Lea, E. J., &
Dawson, A. P. (2000). Interaction of luminal calcium and cytosolic ATP
in the control of type 1 inositol (1,4,5)-trisphosphate receptor
channels. The Journal of Biological Chemistry, 275(46), 36049–36055.
https://doi.org/10.1074/jbc.M000970200
Timerman, A. P., Ogunbumni, E., Freund, E., Wiederrecht, G.,
Marks, A. R., & Fleischer, S. (1993). The calcium release channel
of sarcoplasmic reticulum is modulated by FK-506-binding protein.
Dissociation and reconstitution of FKBP-12 to the calcium release
channel of skeletal muscle sarcoplasmic reticulum. The Journal of
Biological Chemistry, 268(31), 22992–22999.
Timerman, A. P., Onoue, H., Xin, H. B., Barg, S., Copello, J.,
Wiederrecht, G., & Fleischer, S. (1996). Selective binding of FKBP12.6
by the cardiac ryanodine receptor. The Journal of Biological
Chemistry, 271(34), 20385–20391. https://doi.org/10.1074/jbc.271.
34.20385
Tran, Q. K., & Watanabe, H. (2006). Calcium signalling in the endothelium.
Handbook of Experimental Pharmacology, 176(Pt 1), 145–187.
Wallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W.,
Johnston, A., … Mourad, M. (2009). Opportunities to optimize
tacrolimus therapy in solid organ transplantation: Report of the
European consensus conference. Therapeutic Drug Monitoring, 31(2),
139–152.
Wallemacq, P. E., & Reding, R. (1993). FK506 (tacrolimus), a novel
immunosuppressant in organ transplantation: Clinical, biomedical, and
analytical aspects. Clinical Chemistry, 39(11 Pt 1), 2219–2228.
Wang, Y. X., Zheng, Y. M., Mei, Q. B., Wang, Q. S., Collier, M. L.,
Fleischer, S., … Kotlikoff, M. I. (2004). FKBP12.6 and cADPR regulation
of Ca2+ release in smooth muscle cells. American Journal of Physiology.
Cell Physiology, 286(3), C538–C546. https://doi.org/10.1152/ajpcell.
00106.2003
Weidelt, T., & Isenberg, G. (2000). Augmentation of SR Ca2+ release by
rapamycin and FK506 causes K+-channel activation and membrane
hyperpolarization in bladder smooth muscle. British Journal of
Pharmacology, 129(7), 1293–1300. https://doi.org/10.1038/sj.bjp.
0703223
Wilasrusmee, C., Da Silva, M., Singh, B., Siddiqui, J., Bruch, D., Kittur, S., …
Kittur, D. S. (2003). Morphological and biochemical effects of immuno-
suppressive drugs in a capillary tube assay for endothelial dysfunction.
Clinical Transplantation, 17(Suppl 9), 6–12.
Wilson, C., Lee, M., & McCarron, J. G. (2016). Acetylcholine released by
endothelial cells facilitates flow-mediated dilatation. The Journal of
Physiology, 594, 7267–7307. https://doi.org/10.1113/JP272927
Wilson, C., Lee, M. D., Heathcote, H. R., Zhang, X., Buckley, C.,
Girkin, J. M., … McCarron, J. (2019). Mitochondrial ATP
production provides long-range control of endothelial inositol
trisphosphate-evoked calcium signaling. The Journal of Biological
Chemistry, 294(3), 737–758. https://doi.org/10.1074/jbc.RA118.
005913
Wilson, C., Saunter, C. D., Girkin, J. M., & McCarron, J. G. (2015).
Pressure-dependent regulation of Ca2+ signaling in the vascular
endothelium. The Journal of Physiology, 593, 5231–5253. https://doi.
org/10.1113/JP271157
Wilson, C., Saunter, C. D., Girkin, J. M., & McCarron, J. G. (2016).
Clusters of specialized detector cells provide sensitive and high fidelity
receptor signaling in intact endothelium. The FASEB Journal, 30,
2000–2013. https://doi.org/10.1096/fj.201500090
Xiao, J., Tian, X., Jones, P. P., Bolstad, J., Kong, H., Wang, R., … Chen, S. R.
(2007). Removal of FKBP12.6 does not alter the conductance and
18 BUCKLEY ET AL.
activation of the cardiac ryanodine receptor or the susceptibility
to stress-induced ventricular arrhythmias. The Journal of Biological
Chemistry, 282(48), 34828–34838. https://doi.org/10.1074/jbc.
M707423200
Yasutsune, T., Kawakami, N., Hirano, K., Nishimura, J., Yasui, H.,
Kitamura, K., & Kanaide, H. (1999). Vasorelaxation and inhibition of
the voltage-operated Ca2+ channels by FK506 in the porcine coronary
artery. British Journal of Pharmacology, 126(3), 717–729. https://doi.
org/10.1038/sj.bjp.0702339
Zheng, Y. M., Mei, Q. B., Wang, Q. S., Abdullaev, I., Lai, F. A., Xin, H. B., …
Wang, Y. X. (2004). Role of FKBP12.6 in hypoxia- and norepinephrine-
induced Ca2+ release and contraction in pulmonary artery myocytes.
Cell Calcium, 35(4), 345–355.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Buckley C, Wilson C, McCarron JG.
FK506 regulates Ca2+ release evoked by inositol 1,4,5-
trisphosphate independently of FK-binding protein in
endothelial cells. Br J Pharmacol. 2020;1–19. https://doi.org/
10.1111/bph.14905
BUCKLEY ET AL. 19
